Faculty
Shunqiang Li.jpg

Shunqiang Li, PhD

Assistant Professor
Department of Medicine
Oncology Division
Molecular Oncology

Research Interests

  • Patient-derived tumor xenograft (PDX) models
  • Cancer genomics and proteomics
  • Preclinical study of anticancer drugs
  • Personalized cancer therapy

Contact

  • 314-747-9311 (lab)
  • 314-747-9320 (fax)
  • 4515 McKinley Research Building, Room 3307 (office)
  • Division of Oncology
    Breast Oncology Section
    Campus Box 8076
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Publications

  • Loss of MutL disrupts Chk2-dependent cell cycle control through CDK4/6 to promote intrinsic endocrine therapy resistance in primary breast cancer
    Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ
    Cancer Discov 2017 Aug 11; [Epub ahead of print]
  • Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner
    Wang X, Mooradian AD, Erdmann-Gilmore P, Zhang Q, Viner R, Davies SR, Huang KL, Bomgarden R, Van Tine BA, Shao J, Ding L, Li S, Ellis MJ, Rogers JC, Townsend RR, Fenyo D, Held JM
    Sci Signal 2017 Aug 8;10(491)
  • Breast cancer neoantigens can induce CD8+ T-cell responses and antitumor immunity
    Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE
    Cancer Immunol Res 2017 Jul;5(7):516-523
  • Targeted degradation of BET proteins in triple-negative breast cancer
    Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S
    Cancer Res 2017 May 1;77(9):2476-2487
  • Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
    Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyo D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L
    Nat Commun 2017 Mar 28;8:14864
  • Patient-derived xenograft (PDX) models in basic and translational breast cancer research
    Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT
    Cancer Metastasis Rev 2016 Dec;35(4):547-573
  • Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
    Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX
    Oncotarget 2016 Aug 30;7(35):56864-56875
  • Reactivation of p53 by MDM2 inhibitor MI-77301 for the treatment of endocrine-resistant breast cancer
    Lu J, McEachern D, Li S, Ellis MJ, Wang S
    Mol Cancer Ther 2016 Dec;15(12):2887-2893
  • Proteogenomics connects somatic mutations to signalling in breast cancer
    Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyo D, Ellis MJ, Carr SA
    NCI CPTAC (Contributors include: Li S)

    Nature 2016 May 25;534(7605):55-62
  • Reproducibility of differential proteomic technologies in CPTAC fractionated xenografts
    Tabb DL, Wang X, Carr SA, Clauser KR, Mertins P, Chambers MC, Holman JD, Wang J, Zhang B, Zimmerman LJ, Chen X, Gunawardena HP, Davies SR, Ellis MJ, Li S, Townsend RR, Boja ES, Ketchum KA, Kinsinger CR, Mesri M, Rodriguez H, Liu T, Kim S, McDermott JE, Payne SH, Petyuk VA, Rodland KD, Smith RD, Yang F, Chan DW, Zhang B, Zhang H, Zhang Z, Zhou JY, Liebler DC
    J Proteome Res 2016 Mar 4;15(3):691-706
  • An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer
    Ruggles KV, Tang Z, Wang X, Grover H, Askenazi M, Teubl J, Cao S, McLellan MD, Clauser KR, Tabb DL, Mertins P, Slebos R, Erdmann-Gilmore P, Li S, Gunawardena HP, Xie L, Liu T, Zhou JY, Sun S, Hoadley KA, Perou CM, Chen X, Davies SR, Maher CA, Kinsinger CR, Rodland KD, Zhang H, Zhang Z, Ding L, Townsend RR, Rodriguez H, Chan D, Smith RD, Liebler DC, Carr SA, Payne S, Ellis MJ, Fenyo D
    Mol Cell Proteomics 2016 Mar;15(3):1060-71
  • QuantFusion: novel unified methodology for enhanced coverage and precision in quantifying global proteomic changes in whole tissues
    Gunawardena HP, O'Brien J, Wrobel JA, Xie L, Davies SR, Li S, Ellis MJ, Qaqish BF, Chen X
    Mol Cell Proteomics 2016 Feb;15(2):740-51
  • Integrated bottom-up and top-down proteomics of patient-derived breast tumor xenografts
    Ntai I, LeDuc RD, Fellers RT, Erdmann-Gilmore P, Davies SR, Rumsey J, Early BP, Thomas PM, Li S, Compton PD, Ellis MJ, Ruggles KV, Fenyo D, Boja ES, Rodriguez H, Townsend RR, Kelleher NL
    Mol Cell Proteomics 2016 Jan;15(1):45-56
  • Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer
    Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S
    Clin Cancer Res 2015 Nov 15;21(22):5121-30
  • Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes
    Xu Z, Wu C, Xie F, Slysz GW, Tolic N, Monroe ME, Petyuk VA, Payne SH, Fujimoto GM, Moore RJ, Fillmore TL, Schepmoes AA, Levine DA, Townsend RR, Davies SR, Li S, Ellis M, Boja E, Rivers R, Rodriguez H, Rodland KD, Liu T, Smith RD
    J Proteome Res 2015 Jan 2;14(1):422-33
  • Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth
    Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, Herndon J, Cohoon TJ, Fleming T, Tamayo P, Mesirov JP, Ogino S, Wong KK, Ellis MJ, Hahn WC, Barbie DA, Gillanders WE
    J Clin Invest 2014 Dec 1;124(12):5411-5423
  • Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels
    Mertins P, Yang F, Liu T, Mani DR, Petyuk VA, Gillette MA, Clauser KR, Qiao JW, Gritsenko MA, Moore RJ, Levine DA, Townsend R, Erdmann-Gilmore P, Snider JE, Davies SR, Ruggles KV, Fenyo D, Kitchens RT, Li S, Olvera N, Dao F, Rodriguez H, Chan DW, Liebler D, White F, Rodland KD, Mills GB, Smith RD, Paulovich AG, Ellis M, Carr SA
    Mol Cell Proteomics 2014 Jul;13(7):1690-704
  • Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
    Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, Deschryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ
    Cell Rep 2013 Sep 26;4(6):1116-30
  • Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models
    Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX
    Mol Cancer Ther 2013 Aug;12(8):1665-75
  • Activating HER2 mutations in HER2 gene amplification negative breast cancer
    Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ
    Cancer Discov 2013 Feb;3(2):224-37
  • Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
    Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H
    J Clin Invest 2012 Apr 2;122(4):1541-52
  • Targeting the Akt/mTOR pathway in Brca1-deficient cancers
    Xiang T, Jia Y, Sherris D, Li S, Wang H, Lu D, Yang Q
    Oncogene 2012 Jun 7;31(23):2876-87
  • Genome remodelling in a basal-like breast cancer metastasis and xenograft
    Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin L, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du F, Hawkins AE, O'Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM Jr, Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER
    Nature 2010 Apr 15;464(7291):999-1005
  • WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells
    Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Hoang BH, Zi X
    Mol Cancer Ther 2009 Feb;8(2):458-68
  • Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach
    Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F
    Nat Med 2005 Aug;11(8):867-74